ResultsIQ

ResultsIQ › Latest results › Nath Bio-Genes (India) Limited

Nath Bio-Genes (India) Limited Q4 FY26 earnings call summary

NSE: NATHBIOGEN · BSE: 537291

Earnings call of 5 May 2026, summarised by AI from the filing.

Nath Bio-Genes filed the audio recording of its 05th May 2026 conference call on the audited results for the quarter and year ended 31st March 2026.

Key takeaways

  1. Conference call Held on 05th May 2026 at 4:00 PM to discuss the audited financial results for the quarter and year ended 31st March 2026.
  2. Audio recording Available on the company's website.
  3. Filing Submitted to BSE and NSE under Regulation 30 of SEBI LODR Regulations, 2015.
  4. Signatory Amol Gupta, Chief Financial Officer.

Original filing on BSE

Nath Bio-Genes (India) Limited Q1 FY27 results

As filed: Revenue ₹328 cr (+16% year on year), EBITDA ₹35.2 cr (−8% year on year), PAT ₹32.3 cr (−13% year on year), EBITDA margin 10.7% (−268 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹45.7 cr (−7% year on year), EBITDA ₹6.6 cr (+120% year on year), PAT ₹3.8 cr (+1% year on year), EBITDA margin 14.5% (+834 bps). Score 40 of 100, In line with trend. Revenue and profit before exceptional items growth were well below the company's own trend; EBITDA growth was well above it. EBITDA margin rose 834 bps year on year. Other income 38% of PBT. Tax rate 40%. Revenue fell 31% from last quarter. Share price after the results: −8.6% in 30 days (Nifty 500: −1.7%).
  • Q3 FY26: Revenue ₹66.0 cr (+78% year on year), EBITDA ₹3.6 cr (−60% year on year), PAT ₹1.6 cr (−105% year on year), EBITDA margin 5.4% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was well above the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 1000 bps year on year. Other income 70% of PBT. Tax rate 35%. Consolidated profit -46% but standalone +141%. Profit fell 107% from last quarter. Share price after the results: −1.5% in 30 days (Nifty 500: −1.1%).
  • Q2 FY26: Revenue ₹44.0 cr (+38% year on year), EBITDA ₹6.0 cr (+20% year on year), PAT ₹3.0 cr (+200% year on year), EBITDA margin 13.6% (−199 bps). Score 67 of 100, Above trend. Revenue and profit before exceptional items growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin fell 199 bps year on year. Other income 40% of PBT. Revenue fell 85% from last quarter. Share price after the results: −7.2% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹284 cr (+16% year on year), EBITDA ₹38.0 cr (+3% year on year), PAT ₹37.0 cr (+12% year on year), EBITDA margin 13.4% (−178 bps). Score 45 of 100, In line with trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin fell 178 bps year on year. Tax rate 3%. Share price after the results: −24.7% in 28 days (Nifty 500: −3.6%).
  • Q4 FY25: Revenue ₹49.0 cr (+14% year on year), EBITDA ₹3.0 cr (−40% year on year), PAT ₹5.0 cr (+67% year on year), EBITDA margin 6.1% (−551 bps). Score 34 of 100, Below trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was well below it. EBITDA margin fell 551 bps year on year. Other income 80% of PBT. Profit rose ₹2.0 cr on a year ago, more than the ₹1.0 cr it added the year before. Share price after the results: +19.4% in 30 days (Nifty 500: +3.4%).
  • Q3 FY25: Revenue ₹37.0 cr (+16% year on year), EBITDA ₹9.0 cr (+50% year on year), PAT ₹3.0 cr (−25% year on year), EBITDA margin 24.3% (+557 bps). Score 62 of 100, In line with trend. EBITDA margin rose 557 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹32.0 cr (+39% year on year), EBITDA ₹5.0 cr (0% year on year), PAT ₹1.0 cr (−50% year on year), EBITDA margin 15.6% (−611 bps). Score 31 of 100, Below trend. EBITDA margin fell 611 bps year on year. Tax rate 0%. Consolidated profit -50% but standalone +50%. Not enough history for a trend yet: scored on growth alone. Revenue fell 87% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Nath Bio-Genes (India) Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.